Euclidean Capital’s Tenaya Therapeutics TNYA Stock Holding History

Euclidean Capital’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$703K	Hold	1,015,705	–	–	0.18%	9
2025 Q4	$723K	Hold	1,015,705	–	–	0.2%	11
2025 Q3	$1.65M	Hold	1,015,705	–	–	0.69%	9
2025 Q2	$621K	Hold	1,015,705	–	–	0.2%	10
2025 Q1	$579K	Hold	1,015,705	–	–	0.22%	10
2024 Q4	$1.45M	Hold	1,015,705	–	–	0.2%	8
2024 Q3	$1.96M	Hold	1,015,705	–	–	0.22%	9
2024 Q2	$3.15M	Hold	1,015,705	–	–	0.4%	8
2024 Q1	$5.31M	Hold	1,015,705	–	–	0.68%	9
2023 Q4	$3.29M	Hold	1,015,705	–	–	0.37%	10
2023 Q3	$2.59M	Buy	1,015,705 +100,000	+11%	+$419K	0.57%	10
2023 Q2	$5.38M	Hold	915,705	–	–	1.38%	10
2023 Q1	$2.61M	Hold	915,705	–	–	2.29%	9
2022 Q4	$1.84M	Hold	915,705	–	–	1.72%	10
2022 Q3	$2.66M	Hold	915,705	–	–	2.47%	8
2022 Q2	$5.16M	Hold	915,705	–	–	4.38%	7
2022 Q1	$10.8M	Hold	915,705	–	–	6.27%	6
2021 Q4	$17.4M	Hold	915,705	–	–	9.87%	4
2021 Q3	$18.9M	Buy	+915,705	New	+$19.7M	9.19%	4

Other funds holding TNYA

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BGM

Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Euclidean Capital's TNYA Position: Q1 2026 in Review

Euclidean Capital held its Tenaya Therapeutics (TNYA) position steady in Q1 2026 at 1,015,705 shares worth $703K. The position accounts for 0.18% of the portfolio, ranked #9.

Euclidean Capital first reported a position in TNYA in Q3 2021 and has held it in 19 quarters since. The position peaked at $18.9M in Q3 2021. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

Euclidean Capital held 1,015,705 shares of Tenaya Therapeutics worth $703K as of Q1 2026.
Euclidean Capital left its Tenaya Therapeutics share count unchanged in Q1 2026.
Tenaya Therapeutics made up 0.18% of Euclidean Capital's portfolio in Q1 2026, its #9 holding.
Euclidean Capital first reported a position in Tenaya Therapeutics in Q3 2021 and has held it in 19 quarters since.
Euclidean Capital's Tenaya Therapeutics position peaked at $18.9M in Q3 2021.
103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on Euclidean Capital's 13F filing for Q1 2026, filed 15 May 2026.